Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) Senior Officer Jared Ryan Kelly bought 50,400 shares of the firm's stock in a transaction on Wednesday, July 16th. The shares were bought at an average cost of C$1.63 per share, for a total transaction of C$82,284.50.
Oncolytics Biotech Stock Down 2.8%
ONC traded down C$0.05 during midday trading on Friday, hitting C$1.73. The company had a trading volume of 245,934 shares, compared to its average volume of 147,357. Oncolytics Biotech Inc. has a 52 week low of C$0.44 and a 52 week high of C$2.08. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The company has a market capitalization of C$133.34 million, a price-to-earnings ratio of -4.82 and a beta of 1.35. The stock's 50 day moving average price is C$0.92 and its 200 day moving average price is C$0.95.
Wall Street Analysts Forecast Growth
Separately, Jones Trading cut shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.
View Our Latest Research Report on Oncolytics Biotech
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access